Advisor Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Advisor Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$249K	Sell	5,450 -307	-5%	-$12.2K	﹤0.01%	2216
2019 Q3	$204K	Sell	5,757 -389	-6%	-$14.5K	﹤0.01%	2318
2019 Q2	$245K	Sell	6,146 -15,871	-72%	-$624K	﹤0.01%	2147
2019 Q1	$916K	Buy	22,017 +17,986	+446%	+$731K	0.01%	1150
2018 Q4	$148K	Buy	4,031 +1	+0%	+$43	﹤0.01%	2330
2018 Q3	$196K	Buy	4,030 +307	+8%	+$14.5K	﹤0.01%	2180
2018 Q2	$160K	Buy	3,723 +1	+0%	+$42	﹤0.01%	2151
2018 Q1	$156K	Sell	3,722 -310	-8%	-$13.5K	﹤0.01%	2176
2017 Q4	$175K	Buy	4,032 +542	+16%	+$23K	﹤0.01%	2119
2017 Q3	$149K	Buy	3,490 +1	+0%	+$42	﹤0.01%	2083
2017 Q2	$150K	Sell	3,489 -48	-1%	-$2.02K	﹤0.01%	1991
2017 Q1	$148K	Sell	3,537 -290	-8%	-$11.8K	﹤0.01%	1879
2016 Q4	$150K	Sell	3,827 -227	-6%	-$9.24K	﹤0.01%	1780
2016 Q3	$179K	Sell	4,054 -319	-7%	-$14.5K	﹤0.01%	1605
2016 Q2	$181K	Buy	+4,373	New	+$185K	﹤0.01%	1533

Other funds holding XPH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Advisor Group's XPH Position: Q4 2019 in Review

Advisor Group reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 5.3% in Q4 2019, selling an estimated $12.2K and leaving 5,450 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Advisor Group first reported a position in XPH in Q2 2016 and has held it in 15 quarters since. The position peaked at $916K in Q1 2019. 75 funds tracked by Wall St. Rank hold XPH as of Q4 2019.

Advisor Group held 5,450 shares of State Street SPDR S&P Pharmaceuticals ETF worth $249K as of Q4 2019.
Advisor Group sold 307 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2019, an estimated $12.2K.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2216 holding.
Advisor Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2016 and has held it in 15 quarters since.
Advisor Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $916K in Q1 2019.
75 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.